Humanwell Puracap Pharmaceuticals Wuhan Co. Ltd.

Main study purpose: According to the relevant provisions of bioequivalence test, cyclosporine soft capsules (trade name: NEORAL®, specification: 100 mg) of Novartis Pharmaceuticals Corporation as the licensee were selected as the reference preparation, and the test preparation cyclosporine soft capsules (specification: 100 mg) produced and provided by Renfu Puke Pharmaceutical (Wuhan) Co., Ltd. were used for human bioequivalence test under postprandial administration conditions to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under postprandial administration conditions. Secondary study purpose: To observe the safety of oral administration of the test preparation cyclosporine soft capsules (specification: 100 mg) and the reference preparation cyclosporine soft capsules (trade name: NEORAL®, specification: 100 mg) by healthy participants.

Main study purpose: According to the relevant provisions of bioequivalence test, cyclosporine soft capsules (trade name: NEORAL®, specification: 100 mg) with Novartis Pharmaceuticals Corporation as the licensee were selected as the reference preparation, and the test preparation cyclosporine soft capsules (specification: 100 mg) produced and provided by Renfu Puke Pharmaceutical (Wuhan) Co., Ltd. were used for human bioequivalence test under fasting conditions, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting conditions. Secondary study purpose: To observe the safety of oral administration of the test preparation cyclosporine soft capsules (specification: 100 mg) and the reference preparation cyclosporine soft capsules (trade name: NEORAL®, specification: 100 mg) by healthy participants.